SCHEMBL4716406

SCHEMBL4716406

O=C(Cl)c1cc(S(=O)(=O)N2CCCCC2)ccc1Cl

nearest known ligand 0.78

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.78
ALDH1A1 P00352 4/20 0.61
KDM4E B2RXH2 3/20 0.61
MAPT P10636 2/20 0.61
LMNA P02545 2/20 0.61
GFER P55789 1/20 0.61
POLB P06746 1/20 0.60
KMT2A Q03164 2/20 0.59
CYP3A4 P08684 1/20 0.59
MEN1 O00255 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.58
NPSR1 Q6W5P4 1/20 0.58
NPBWR1 P48145 1/20 0.57
MCHR1 Q99705 1/20 0.57
HTT P42858 1/20 0.57
HSD17B10 Q99714 1/20 0.57
MCOLN3 Q8TDD5 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1708867 0.88 TSHR (1.00) TSHRALDH1A1KDM4EMAPTLMNA
SCHEMBL3921818 0.86 TSHR (0.97) TSHRALDH1A1KDM4EMAPTLMNA
SCHEMBL8803271 0.81 TSHR (0.67) TSHRALDH1A1KDM4EMAPTLMNA
SCHEMBL493045 0.80 POLB (0.72) TSHRALDH1A1KDM4EMAPTPOLB
SCHEMBL11169495 0.80 KMT2A (0.61) TSHRALDH1A1KDM4EMAPTPOLB
SCHEMBL11169492 0.80 KMT2A (0.61) TSHRALDH1A1KDM4EMAPTPOLB
SCHEMBL8802388 0.79 TSHR (0.65) TSHRALDH1A1KDM4EMAPTLMNA
SCHEMBL4716186 0.79 TSHR (0.64) TSHRALDH1A1KDM4EMAPTLMNA
SCHEMBL8803257 0.79 TSHR (0.64) TSHRALDH1A1KDM4EMAPTLMNA
SCHEMBL494192 0.79 KDM4E (0.74) TSHRALDH1A1KDM4EPOLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1615904-B1 SUBSTITUTED BENZOSULPHONAMIDES AS POTENTIATORS OF GLUTAMATE RECEPTORS ASTRAZENECA AB (SE) 2008-02-27 EP disclosed
US-20070021606-A1 Therapeutic compounds ASTRAZENECA AB (SE) 2007-01-25 US disclosed
EP-1615904-A2 SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS AstraZeneca AB (SE) 2006-01-18 EP disclosed
WO-2004092135-A2 SUBSTITUTED BENZOSULPHONAMIDE AS POTENTIATORS OF GLUTAMATE RECEPTORS ASTRAZENECA (SE) 2004-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021606-A1 Therapeutic compounds GRIN1, GRIN3A, GRM2 TSHR 685/4885ALDH1A1 1721/4885KDM4E 3991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.